Search company, investor...
Search
JumpCode company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

jumpcodegenomics.com

Stage

Series B | Alive

Total Raised

$26.01M

Last Raised

$21M | 2 yrs ago

About JumpCode

JumpCode offers CRISPR-mediated rRNA depletion kits to remove nucleic acids from sequencing workflows to improve sensitivity and performance.

JumpCode Headquarters Location

1160 Cape Aire Lane

Carlsbad, California, 92008,

United States

(858)336-4827

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing JumpCode

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

JumpCode is included in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

JumpCode Patents

JumpCode has filed 8 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/10/2018

5/24/2022

Molecular biology, Genetics, DNA, Biotechnology, Gene expression

Grant

Application Date

8/10/2018

Grant Date

5/24/2022

Title

Related Topics

Molecular biology, Genetics, DNA, Biotechnology, Gene expression

Status

Grant

Latest JumpCode News

BARDA Taps Jumpcode for Pathogen Detection Program

May 20, 2022

BARDA Taps Jumpcode for Pathogen Detection Program   With that goal in mind, on May 3, the Biomedical Advanced Research and Development Authority (BARDA) announced a program from its Division of Research, Innovation and Ventures (DRIVe) to collaborate with industry and academic partners to develop advanced diagnostic capabilities that cover existing and new respiratory viruses in a single test. Yaron HakakCEOJumpcode Genomics   “The lack of preparedness for detecting a highly infectious virus pathogen like SARS-CoV-2 has caused enormous harm to public health and our economy worldwide,” said Jumpcode CEO Yaron Hakak, adding that it took 60 days for first COVID PCR test to be made and an additional 270 days to deploy 800,000 tests. “And that was at a time when the estimated need was over 6 million tests per day.”   Needle in Haystack Solution   Hakak describes Jumpcode as a genome technology company that “significantly improves detection sensitivity in next generation sequencing (NGS).”   Using a solution called CRISPRclean, the Jumpcode platform acts as “molecular scissors” to cut out in a targeted way molecules researchers are not interested in and removes them from the NGS workflow. BARRDA’s interest in tapping Jumpcode for the DRIVe program is because its platform is akin to PCR – a diagnostic test that determines infection by analyzing a sample for presence of a virus’ genetic material. “In fact, it’s the exact inverse of PCR,” Hakak explained. “Our technology allows you to deplete or remove sequences that are not of interest to you so that you can see everything that remains. In essence, it addresses the needle in a haystack problem that exists in genomics. Our technology removes the haystack so you can see the remaining needles.”   Those remaining needles can be viruses, bacteria, fungi or parasites – any potential pathogen that is harmful to the body would be detected. “A universal infectious disease test or agnostic diagnostic; one test to detect any virus, whether RNA or DNA by removing the noise associated with the host,” Hakak said. “That’s the beauty of the assay. It doesn’t need to know what you’re looking for – it needs to know what you’re not looking for.” Keith BrownFounder, CTOJumpcode Genomics Keith Brown, founder and CTO of Jumpcode Genomics, stressed the importance of better diagnostic tests because the emergence of another pandemic-casing virus is “highly likely” and that current diagnostic tools are only designed to look for known pathogens once they have already begun to spread. “The work we’re doing with BARDA will enable the detection of any respiratory pathogen, known or unknown, that could cause a pandemic in the future,” he said. “BARDA’s investments will ensure our nation’s future response strategy is not limited by testing capacity.”     Hakak said the deal with BARDA includes monetary support for the work based on milestones in achieving a population-scale agnostic test for respiratory virus. Jumpcode has already completed a study demonstrating utility of its technology that showed equivalent detection sensitivity as a PCR in detecting COVID-19. Jumpcode showed it could detect any variant of COVID; detect co-infections; and could also detect the immune response of individual patients, which could aid doctors in treatment. As part of the BARDA contract, Jumpcode now has three main goals to achieve: The company must further optimize its existing CRISPRclean reagent product geared toward metagenomic or infectious disease analysis; validate the sensitivity of its assay in detecting other respiratory pathogens beyond COVID, such as influenzas; and validate its work on existing automation solutions from sample extraction through laboratory preparation. Hakak said Jumpcode is already working with a large automation service provider to validate the work on their platform. According to BARDA, partners in the DRIVe program could potentially pursue appropriate regulatory pathways towards commercialization for their BARDA-funded results. Future commercial applications could include biosurvelliance and point-of-care testing. Hakak said he is looking forward to working with BARDA for “a better understanding of the path towards commercializing infectious disease solutions that are based on NSG platforms.”

JumpCode Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

JumpCode Rank

  • Where is JumpCode's headquarters?

    JumpCode's headquarters is located at 1160 Cape Aire Lane, Carlsbad.

  • What is JumpCode's latest funding round?

    JumpCode's latest funding round is Series B.

  • How much did JumpCode raise?

    JumpCode raised a total of $26.01M.

  • Who are the investors of JumpCode?

    Investors of JumpCode include Baird Capital Partners, LYZZ Capital and Arboretum Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.